0 Items
Select Page

Epstein Barr Virus

The Epstein–Barr virus (EBV) is one of the most commonly found viruses in humans and is best known for causing infectious mononucleosis (glandular fever). EBV is also associated with particular forms of cancer, including Hodgkin’s lymphoma, Burkitt’s lymphoma, gastric cancer and nasopharyngeal carcinoma. About 200,000 cancer cases per year are thought to be attributable to EBV.

The Native Antigen Company have developed recombinant antigens for use in EBV research and assay development.

Epstein Barr Virus Background

Epstein Barr Virus (EBV) is a double-stranded DNA, enveloped virus, with a large genome encoding 200 proteins. Epstein Barr virus, also known as Herpes virus 4 (HHV4), belongs to the gammaherpesvirinae subgroup of the Herpesvirus family.

EBV is widely distributed and is estimated to affect around 90% of the human population. In developing countries, most children contract EBV infection at an early age. In developed countries, primary EBV infection is more common in adolescents and adults. The Epstein-Barr virus is commonly spread from human-to-human through saliva and other body fluids (CDC).

In most cases, EBV Infection is asymptomatic, but some individuals develop infectious mononucleosis, a condition that is generally self-limiting but can cause prolonged fatigue lasting for several months. After primary EBV infection, the virus remains latent and can re-activate under certain circumstances. In immunocompromised patients, EBV infection is associated with various malignancies, autoimmune disease and other chronic and acute illnesses.

Epstein-Barr virus primarily targets B-lymphocytes but is also reported to infect epithelial cells, T-cells, natural killer cells, smooth muscle cells and monocytes (Hutt-Fletcher, L.M.).

Epstein Barr Virus Antigens

The Native Antigen Company has developed and produces recombinant Epstein Barr Virus gp125 antigens using our proprietary mammalian expression system. These antigens are suitable for research and development into Epstein-Barr virus biology and in the development of immunoassays.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Why We Need Antigen and Antibody Tests for COVID-19

RT-PCR is the workhorse of viral diagnosis and has been invaluable in COVID-19 case confirmation and isolation guidance. However, while fast and sensitive, PCR suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To...

Gonorrhea: What’s Currently in the Clinical Pipeline?

This article was written by our friends at Infectious Diseases Hub, a free-to-access website that aims to deliver up-to-date, essential research and information on all aspects of microbiology, virology, mycology and parasitology – from bench to bedside....

Novel Coronavirus Antigens Now Available

The Native Antigen Company is now offering recombinant S1 and S2 glycoproteins for SARS-CoV-2 (Covid-19) in response to urgent demand. These reagents are suitable for use in basic research and the development of diagnostics and vaccines.These antigens have been...

The Why and How of Protein Conjugation

In this blog, Lead Assay Development Scientist, Toni Ertl discusses the basics of protein conjugation and introduces our new range of conjugation kits for the labelling of antigens and antibodies.Detecting Proteins If you’re trying to detect or measure the presence...

Going Viral: Why We Need New Diagnostics For a Safe and Effective Dengue Vaccine

This article is taken from European Biopharmaceutical Review January 2020, pages 44-46. © Samedan Ltd.The Dengue VirusDengue is the world’s most prevalent and consequential arboviral disease. Current estimates indicate that as many as 390 million dengue infections...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

14 + 9 =

Live Customer Feedback

Join our mailing list

* indicates required